Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Factors associated with ocular adverse event after immune checkpoint inhibitor treatment.

Tytuł:
Factors associated with ocular adverse event after immune checkpoint inhibitor treatment.
Autorzy:
Kim YJ; Department of Ophthalmology, Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, Republic of Korea.
Lee JS; Department of Ophthalmology, Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, Republic of Korea.
Lee J; Department of Ophthalmology, Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, Republic of Korea.
Lee SC; Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Republic of Korea.
Kim TI; Department of Ophthalmology, Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, Republic of Korea.
Byeon SH; Department of Ophthalmology, Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, Republic of Korea.
Lee CS; Department of Ophthalmology, Institute of Vision Research, Severance Hospital, Yonsei University College of Medicine, Yonsei-ro 50-1, Seodaemun-gu, Seoul, Republic of Korea. .
Źródło:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Dec; Vol. 69 (12), pp. 2441-2452. Date of Electronic Publication: 2020 Jun 17.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York, NY : Springer International, c1982-
MeSH Terms:
Antineoplastic Agents, Immunological/*adverse effects
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Eye Diseases/*epidemiology
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*adverse effects
Adult ; Aged ; Aged, 80 and over ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Drug Substitution/adverse effects ; Eye Diseases/chemically induced ; Eye Diseases/immunology ; Female ; Humans ; Male ; Middle Aged ; Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors ; Neoplasms/immunology ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Retrospective Studies ; Risk Factors
Grant Information:
NRF-2019R1A2C2002393 National Research Foundation of Korea
Contributed Indexing:
Keywords: Immune checkpoint inhibitor; Intraocular inflammation; Ocular adverse event; Risk factor
Substance Nomenclature:
0 (Antineoplastic Agents, Immunological)
0 (B7-H1 Antigen)
0 (CD274 protein, human)
0 (CTLA-4 Antigen)
0 (CTLA4 protein, human)
0 (PDCD1 protein, human)
0 (Programmed Cell Death 1 Receptor)
0 (Protein Kinase Inhibitors)
EC 2.7.11.1 (BRAF protein, human)
EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
Entry Date(s):
Date Created: 20200620 Date Completed: 20201207 Latest Revision: 20201214
Update Code:
20240105
DOI:
10.1007/s00262-020-02635-3
PMID:
32556494
Czasopismo naukowe
Ocular adverse events (OAEs) including vision-threatening intraocular inflammation after immune checkpoint inhibitor (ICI) treatment have been increasingly reported; however, the risk factors associated with OAEs remain elusive. Here, we determined the factors associated with OAEs after ICI treatment. We analyzed 40 consecutive patients who experienced OAEs after ICI treatments. The OAEs included anterior uveitis, chorioretinitis, papillitis, foveal interdigitation zone thickening/serous retinal detachment (IZT/SRD), retinal vascular occlusion, and strabismus and ptosis. Of 40 patients, 18 (45%) were treated with atezolizumab, 13 (33%) with pembrolizumab, 7 (18%) with nivolumab, 1 (3%) with ipilimumab/nivolumab, and the other 1 (3%) with durvalumab/tremelimumab. BRAF/MEK inhibitors were concurrently used in 19 (48%) patients. Occurrence of intraocular inflammation was significantly associated with previous ocular surgery and trauma history (P = 0.015) and pembrolizumab use (P = 0.031). Neuro-ophthalmic complications and IZT/SRD were associated with brain metastasis (P = 0.005) and treatment with BRAF/MEK inhibitor (P < 0.001), respectively. In extensive literature review for clinical cases, we identified seven cases with intraocular inflammation, which were not observed with ipilimumab treatment, that occurred after a change of the drug to pembrolizumab. Collectively, these findings provide better understandings of OAEs after ICI treatment.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies